Amicus Therapeutics, Inc. (NASDAQ:FOLD) Sees Significant Decrease in Short Interest

Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of a significant decline in short interest in February. As of February 15th, there was short interest totalling 14,740,000 shares, a decline of 15.0% from the January 31st total of 17,340,000 shares. Based on an average daily trading volume, of 2,350,000 shares, the days-to-cover ratio is currently 6.3 days.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics in the 3rd quarter worth about $26,000. Hazlett Burt & Watson Inc. raised its holdings in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares during the period. Virtus Fund Advisers LLC purchased a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $29,000. Covestor Ltd raised its holdings in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 2,312 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at about $55,000.

Amicus Therapeutics Stock Down 0.2 %

FOLD opened at $9.11 on Wednesday. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The firm has a market cap of $2.80 billion, a P/E ratio of -50.61, a PEG ratio of 1.51 and a beta of 0.61. Amicus Therapeutics has a 52 week low of $8.78 and a 52 week high of $13.53. The business’s fifty day simple moving average is $9.49 and its 200 day simple moving average is $10.32.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Guggenheim boosted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Wells Fargo & Company lowered their price target on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price target (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.